Science & Enterprise subscription

Follow us on Twitter

  • Then "Day at the Races" https://t.co/9VT3sNFSZG
    about 13 hours ago
  • The Forward, America’s Leading Jewish News Organization, Goes All Digital. Third-generation subscriber here and wor… https://t.co/2CdgU2WLwR
    about 15 hours ago
  • Our friends at Statista reported on a survey on how the shutdown is affecting people in the U.S., this weekend's in… https://t.co/AbSCYqzGjI
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Americans Affected by Gov’t Shutdown https://t.co/6uC0lIaMIU #Science #Business
    about 18 hours ago
  • New contributed post on Science and Enterprise: https://t.co/XjQZgoAp3S Hands Off! Robots in Modern Medicine
    about 19 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Start-Ups Saying No Thanks to Venture Capital

Calculator cash calendar

Yesterday, we reported on 2018 being a banner year for venture capital, but the New York Times says a movement of entrepreneurs is looking for other ways to raise money. . . . → Read More: Start-Ups Saying No Thanks to Venture Capital

Spin-Off Gains Seed Funds for Non-Opioid Pain Drug

Molly Shoichet

A company spun-off from a university medical materials lab received start-up funds to develop a non-opioid surgical pain therapy, including a clinical trial. . . . → Read More: Spin-Off Gains Seed Funds for Non-Opioid Pain Drug

Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Neurons illustration

Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Patent Set for Long-Term Drug Capsules

Star-shaped drug delivery

Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities. . . . → Read More: Patent Set for Long-Term Drug Capsules

Companies Partner on High-Resolution 3-D Tissue Printer

Holograph-X bioprinter

Two developers of tissue engineering technologies are building a three-dimensional bioprinter that produces high resolution, finely structured human tissue, including tiny blood vessels. . . . → Read More: Companies Partner on High-Resolution 3-D Tissue Printer

Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Gene therapy lab

Results from the first 2 participants in a clinical trial show transferring healthy genes to patients with sickle cell disease reverses symptoms of the disease that continues for up to 1 year. . . . → Read More: Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Trials OK’d for Inherited Eye Disease Therapy with Crispr

Crispr-Cas9 illustration

The company developing a treatment for a rare inherited eye disease using the genome editing technique Crispr received authorization from the Food and Drug Administration to begin clinical trials. . . . → Read More: Trials OK’d for Inherited Eye Disease Therapy with Crispr

Update – Verily Suspends Glucose-Sensing Contact Lens Project

Smart contact lenses

An initiative developing a contact lens that measures blood glucose levels in tear fluid is now on hold, according to Verily Life Sciences, a division of Alphabet, the parent company of Google. . . . → Read More: Update – Verily Suspends Glucose-Sensing Contact Lens Project

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal